165 related articles for article (PubMed ID: 37615686)
21. Case-control analysis of truncating mutations in DNA damage response genes connects TEX15 and FANCD2 with hereditary breast cancer susceptibility.
Mantere T; Tervasmäki A; Nurmi A; Rapakko K; Kauppila S; Tang J; Schleutker J; Kallioniemi A; Hartikainen JM; Mannermaa A; Nieminen P; Hanhisalo R; Lehto S; Suvanto M; Grip M; Jukkola-Vuorinen A; Tengström M; Auvinen P; Kvist A; Borg Å; Blomqvist C; Aittomäki K; Greenberg RA; Winqvist R; Nevanlinna H; Pylkäs K
Sci Rep; 2017 Apr; 7(1):681. PubMed ID: 28386063
[TBL] [Abstract][Full Text] [Related]
22. Germline RBBP8 variants associated with early-onset breast cancer compromise replication fork stability.
Zarrizi R; Higgs MR; Voßgröne K; Rossing M; Bertelsen B; Bose M; Kousholt AN; Rösner H; Network TC; Ejlertsen B; Stewart GS; Nielsen FC; Sørensen CS
J Clin Invest; 2020 Aug; 130(8):4069-4080. PubMed ID: 32379725
[TBL] [Abstract][Full Text] [Related]
23. Genetic testing by cancer site: stomach.
Chun N; Ford JM
Cancer J; 2012; 18(4):355-63. PubMed ID: 22846738
[TBL] [Abstract][Full Text] [Related]
24. Hereditary breast cancer; Genetic penetrance and current status with BRCA.
Mahdavi M; Nassiri M; Kooshyar MM; Vakili-Azghandi M; Avan A; Sandry R; Pillai S; Lam AK; Gopalan V
J Cell Physiol; 2019 May; 234(5):5741-5750. PubMed ID: 30552672
[TBL] [Abstract][Full Text] [Related]
25. Germline E-cadherin mutations in familial lobular breast cancer.
Masciari S; Larsson N; Senz J; Boyd N; Kaurah P; Kandel MJ; Harris LN; Pinheiro HC; Troussard A; Miron P; Tung N; Oliveira C; Collins L; Schnitt S; Garber JE; Huntsman D
J Med Genet; 2007 Nov; 44(11):726-31. PubMed ID: 17660459
[TBL] [Abstract][Full Text] [Related]
26. Analysis of hereditary cancer syndromes by using a panel of genes: novel and multiple pathogenic mutations.
Tsaousis GN; Papadopoulou E; Apessos A; Agiannitopoulos K; Pepe G; Kampouri S; Diamantopoulos N; Floros T; Iosifidou R; Katopodi O; Koumarianou A; Markopoulos C; Papazisis K; Venizelos V; Xanthakis I; Xepapadakis G; Banu E; Eniu DT; Negru S; Stanculeanu DL; Ungureanu A; Ozmen V; Tansan S; Tekinel M; Yalcin S; Nasioulas G
BMC Cancer; 2019 Jun; 19(1):535. PubMed ID: 31159747
[TBL] [Abstract][Full Text] [Related]
27. Increased Risk of Hereditary Prostate Cancer in Italian Families with Hereditary Breast and Ovarian Cancer Syndrome Harboring Mutations in
D'Elia G; Caliendo G; Tzioni MM; Albanese L; Passariello L; Molinari AM; Vietri MT
Genes (Basel); 2022 Sep; 13(10):. PubMed ID: 36292577
[TBL] [Abstract][Full Text] [Related]
28. Identification of a comprehensive spectrum of genetic factors for hereditary breast cancer in a Chinese population by next-generation sequencing.
Yang X; Wu J; Lu J; Liu G; Di G; Chen C; Hou Y; Sun M; Yang W; Xu X; Zhao Y; Hu X; Li D; Cao Z; Zhou X; Huang X; Liu Z; Chen H; Gu Y; Chi Y; Yan X; Han Q; Shen Z; Shao Z; Hu Z
PLoS One; 2015; 10(4):e0125571. PubMed ID: 25927356
[TBL] [Abstract][Full Text] [Related]
29. A Novel Mutation-BRCA1 Associated Hereditary Haplotype of Intragenic Markers of BRCA1 Gene in a Family with History of Breast Cancer.
Miresmaeili SM; Jafari F
Asian Pac J Cancer Prev; 2019 Feb; 20(2):611-614. PubMed ID: 30806067
[TBL] [Abstract][Full Text] [Related]
30. Identification of germline genetic mutations in patients with pancreatic cancer.
Salo-Mullen EE; O'Reilly EM; Kelsen DP; Ashraf AM; Lowery MA; Yu KH; Reidy DL; Epstein AS; Lincoln A; Saldia A; Jacobs LM; Rau-Murthy R; Zhang L; Kurtz RC; Saltz L; Offit K; Robson ME; Stadler ZK
Cancer; 2015 Dec; 121(24):4382-8. PubMed ID: 26440929
[TBL] [Abstract][Full Text] [Related]
31. Pathologic findings in breast, fallopian tube, and ovary specimens in non-BRCA hereditary breast and/or ovarian cancer syndromes: a study of 18 patients with deleterious germline mutations in RAD51C, BARD1, BRIP1, PALB2, MUTYH, or CHEK2.
Schoolmeester JK; Moyer AM; Goodenberger ML; Keeney GL; Carter JM; Bakkum-Gamez JN
Hum Pathol; 2017 Dec; 70():14-26. PubMed ID: 28709830
[TBL] [Abstract][Full Text] [Related]
32. Using gene carrier probability to select high risk families for identifying germline mutations in breast cancer susceptibility genes.
Chang-Claude J; Dong J; Schmidt S; Shayeghi M; Komitowski D; Becher H; Stratton MR; Royer-Pokora B
J Med Genet; 1998 Feb; 35(2):116-21. PubMed ID: 9507390
[TBL] [Abstract][Full Text] [Related]
33. Germline variation networks in the PI3K/AKT pathway corresponding to familial high-incidence lung cancer pedigrees.
Lin H; Zhang G; Zhang XC; Lian XL; Zhong WZ; Su J; Chen SL; Wu YL
BMC Cancer; 2020 Dec; 20(1):1209. PubMed ID: 33297998
[TBL] [Abstract][Full Text] [Related]
34. Tumor sequencing is useful to refine the analysis of germline variants in unexplained high-risk breast cancer families.
Van Marcke C; Helaers R; De Leener A; Merhi A; Schoonjans CA; Ambroise J; Galant C; Delrée P; Rothé F; Bar I; Khoury E; Brouillard P; Canon JL; Vuylsteke P; Machiels JP; Berlière M; Limaye N; Vikkula M; Duhoux FP
Breast Cancer Res; 2020 Apr; 22(1):36. PubMed ID: 32295625
[TBL] [Abstract][Full Text] [Related]
35. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
[TBL] [Abstract][Full Text] [Related]
36. Germline EMSY sequence alterations in hereditary breast cancer and ovarian cancer families.
Määttä KM; Nurminen R; Kankuri-Tammilehto M; Kallioniemi A; Laasanen SL; Schleutker J
BMC Cancer; 2017 Jul; 17(1):496. PubMed ID: 28738860
[TBL] [Abstract][Full Text] [Related]
37. Whole-exome sequencing of non-BRCA1/BRCA2 mutation carrier cases at high-risk for hereditary breast/ovarian cancer.
Felicio PS; Grasel RS; Campacci N; de Paula AE; Galvão HCR; Torrezan GT; Sabato CS; Fernandes GC; Souza CP; Michelli RD; Andrade CE; Barros BDF; Matsushita MM; Revil T; Ragoussis J; Couch FJ; Hart SN; Reis RM; Melendez ME; Tonin PN; Carraro DM; Palmero EI
Hum Mutat; 2021 Mar; 42(3):290-299. PubMed ID: 33326660
[TBL] [Abstract][Full Text] [Related]
38. The NCCN Criterion "Young Age at Onset" Alone is Not an Indicator of Hereditary Breast Cancer in Iranian Population.
Ebrahimi E; Sellars E; Shirkoohi R; Harirchi I; Ghiasvand R; Mohebbi E; Zendehdel K; Akbari MR
Cancer Prev Res (Phila); 2019 Nov; 12(11):763-770. PubMed ID: 31451522
[TBL] [Abstract][Full Text] [Related]
39. A novel BRCA1 germline mutation promotes triple-negative breast cancer cells progression and enhances sensitivity to DNA damage agents.
Xu K; Shi Y; Wang X; Chen Y; Tang L; Guan X
Cancer Genet; 2019 Nov; 239():26-32. PubMed ID: 31476665
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of the contribution of germline variants in BRCA1 and BRCA2 to uveal and cutaneous melanoma.
Johansson PA; Nathan V; Bourke LM; Palmer JM; Zhang T; Symmons J; Howlie M; Patch AM; Read J; Holland EA; Schmid H; Warrier S; Glasson W; Höiom V; Wadt K; Jönsson G; Olsson H; Ingvar C; Mann G; Brown KM; Hayward NK; Pritchard AL
Melanoma Res; 2019 Oct; 29(5):483-490. PubMed ID: 31464824
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
